医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

製薬

Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions

Apros Therapeutics Announces IND Clearance from U.S. FDA to Initiate the Trial of APR003, an Orally-Administered Gastrointestinal/Liver-Targeted TLR7 Agonist for Treatment of Advanced Colorectal Cancer (CRC) with Malignant Liver Lesions

その他ヘルスバイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: an Orally-Administered Gastrointestinal Apros Therapeutics Announces CRC IND Clearance Liver-Targeted TLR7

2020年09月09日

Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World

Taiwan Innotech Expo (TIE) Showcases Strong Ecosystems in the Post-Pandemic World

バイオテクノロジーヘルスケア医療用品感染症製薬　 TimeLine: Showcases Strong Ecosystems in the Post-Pandemic World Taiwan Innotech Expo TIE

2020年09月09日

Dr. Reddy’s Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. Market

ヘルスケア製薬　 TimeLine: Arthritis Pain in the Market of Over-The-Counter Diclofenac Sodium Topical Gel 1%Reddy's Laboratories Announces the Launch the store brand version of Voltaren

2020年09月09日

GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise

バイオテクノロジーヘルスケア感染症製薬　 TimeLine: AI Expert Atomwise to Expand Hemophilia Franchise GC Pharma Taps Small Molecule

2020年09月09日

CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

バイオテクノロジーヘルスケア製薬遺伝学　 TimeLine: CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

2020年09月08日

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

バイオテクノロジーヘルスケア医療機器腫瘍学製薬　 TimeLine: $562 million Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately USD

2020年09月08日

Zion Pharma Announces Initiation of Phase 1 Study

Zion Pharma Announces Initiation of Phase 1 Study

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Study Zion Pharma Announces Initiation of Phase

2020年09月08日

赞荣医药宣布启动临床一期研究

赞荣医药宣布启动临床一期研究

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: 赞荣医药宣布启动临床一期研究

2020年09月08日

BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

2020年09月04日

Shionogi Granted New Technology Add-on Payment For FETROJA® (Cefiderocol) by CMS

Shionogi Granted New Technology Add-on Payment For FETROJA® (Cefiderocol) by CMS

バイオテクノロジーヘルスケアマネージド・ケア感染症病院腫瘍学製薬　 TimeLine: cefiderocol Shionogi Granted New Technology Add-on Payment For FETROJA

2020年09月04日